225 related articles for article (PubMed ID: 35728703)
21. Modelling of Hepatitis E virus RNA-dependent RNA polymerase genotype 3 from a chronic patient and
Cancela F; Rendon-Marin S; Quintero-Gil C; Houston DR; Gumbis G; Panzera Y; Pérez R; Arbiza J; Mirazo S
J Biomol Struct Dyn; 2023 Feb; 41(2):705-721. PubMed ID: 34861797
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis E Virus Infects Neurons and Brains.
Zhou X; Huang F; Xu L; Lin Z; de Vrij FMS; Ayo-Martin AC; van der Kroeg M; Zhao M; Yin Y; Wang W; Cao W; Wang Y; Kushner SA; Marie Peron J; Alric L; de Man RA; Jacobs BC; van Eijk JJ; Aronica EMA; Sprengers D; Metselaar HJ; de Zeeuw CI; Dalton HR; Kamar N; Peppelenbosch MP; Pan Q
J Infect Dis; 2017 Apr; 215(8):1197-1206. PubMed ID: 28199701
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis E Virus Drug Development.
Kinast V; Burkard TL; Todt D; Steinmann E
Viruses; 2019 May; 11(6):. PubMed ID: 31141919
[TBL] [Abstract][Full Text] [Related]
24. Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation.
Li Y; Li P; Li Y; Zhang R; Yu P; Ma Z; Kainov DE; de Man RA; Peppelenbosch MP; Pan Q
Antiviral Res; 2020 Dec; 184():104967. PubMed ID: 33137361
[TBL] [Abstract][Full Text] [Related]
25. Targeting proteostasis of the HEV replicase to combat infection in preclinical models.
Zhang F; Xu LD; Zhang Q; Wang A; Yu X; Liu S; Chen C; Wu S; Jin J; Lin A; Neculai D; Zhao B; Feng XH; Liang T; Xu P; Huang YW
J Hepatol; 2023 Apr; 78(4):704-716. PubMed ID: 36574921
[TBL] [Abstract][Full Text] [Related]
26. Screening of novel drugs for inhibiting hepatitis E virus replication.
Nishiyama T; Kobayashi T; Jirintai S; Kii I; Nagashima S; Prathiwi Primadharsini P; Nishizawa T; Okamoto H
J Virol Methods; 2019 Aug; 270():1-11. PubMed ID: 31004661
[TBL] [Abstract][Full Text] [Related]
27. Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of hepatitis E virus replication.
Debing Y; Winton J; Neyts J; Dallmeier K
Antiviral Res; 2013 Oct; 100(1):98-101. PubMed ID: 23916729
[TBL] [Abstract][Full Text] [Related]
28. Zinc: A Potential Antiviral Against Hepatitis E Virus Infection?
Kaushik N; Anang S; Ganti KP; Surjit M
DNA Cell Biol; 2018 Jul; 37(7):593-599. PubMed ID: 29897788
[TBL] [Abstract][Full Text] [Related]
29. Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms.
Primadharsini PP; Nagashima S; Nishiyama T; Okamoto H
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896767
[TBL] [Abstract][Full Text] [Related]
30. ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication.
Sooryanarain H; Rogers AJ; Cao D; Haac MER; Karpe YA; Meng XJ
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724761
[TBL] [Abstract][Full Text] [Related]
31. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN-stimulated genes.
Xu L; Zhou X; Wang W; Wang Y; Yin Y; Laan LJ; Sprengers D; Metselaar HJ; Peppelenbosch MP; Pan Q
FASEB J; 2016 Oct; 30(10):3352-3367. PubMed ID: 27328944
[TBL] [Abstract][Full Text] [Related]
32. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
Lanford RE; Guerra B; Lee H; Averett DR; Pfeiffer B; Chavez D; Notvall L; Bigger C
J Virol; 2003 Jan; 77(2):1092-104. PubMed ID: 12502825
[TBL] [Abstract][Full Text] [Related]
33. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients.
Debing Y; Gisa A; Dallmeier K; Pischke S; Bremer B; Manns M; Wedemeyer H; Suneetha PV; Neyts J
Gastroenterology; 2014 Nov; 147(5):1008-11.e7; quiz e15-6. PubMed ID: 25181691
[TBL] [Abstract][Full Text] [Related]
34. A rat model for hepatitis E virus.
Debing Y; Mishra N; Verbeken E; Ramaekers K; Dallmeier K; Neyts J
Dis Model Mech; 2016 Oct; 9(10):1203-1210. PubMed ID: 27483350
[TBL] [Abstract][Full Text] [Related]
35. Ritonavir Blocks Hepatitis E Virus Internalization and Clears Hepatitis E Virus In Vitro with Ribavirin.
Primadharsini PP; Nagashima S; Takahashi M; Murata K; Okamoto H
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366538
[TBL] [Abstract][Full Text] [Related]
36. Antiviral strategies for hepatitis E virus.
Debing Y; Neyts J
Antiviral Res; 2014 Feb; 102():106-18. PubMed ID: 24374149
[TBL] [Abstract][Full Text] [Related]
37. RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production.
Xu L; Wang W; Li Y; Zhou X; Yin Y; Wang Y; de Man RA; van der Laan LJW; Huang F; Kamar N; Peppelenbosch MP; Pan Q
Hepatology; 2017 Jun; 65(6):1823-1839. PubMed ID: 28195391
[TBL] [Abstract][Full Text] [Related]
38. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Dao Thi VL; Debing Y; Wu X; Rice CM; Neyts J; Moradpour D; Gouttenoire J
Gastroenterology; 2016 Jan; 150(1):82-85.e4. PubMed ID: 26408347
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of hepatitis E virus replication by zinc-finger antiviral Protein synergizes with IFN-β.
Yu W; Ji H; Long F; Chen S; He Q; Xia Y; Cong C; Yang C; Wei D; Huang F
J Viral Hepat; 2021 Aug; 28(8):1219-1229. PubMed ID: 33894039
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulation of Natural Killer Cell Function by Ribavirin Involves TYK-2 Activation and Subsequent Increased IFN-γ Secretion in the Context of In Vitro Hepatitis E Virus Infection.
Kupke P; Adenugba A; Schemmerer M; Bitterer F; Schlitt HJ; Geissler EK; Wenzel JJ; Werner JM
Cells; 2023 Jan; 12(3):. PubMed ID: 36766795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
